Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gabriel Steg

Showing results (781-790 of 962) with videos related to

Pageof 97
Sort By:
JAMA|October 28, 2010
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysisJessica L Mega, Tabassome Simon, Jean-Philippe Collet, et al.
International Journal of Cardiology|May 31, 2017
Patterns and associations between DAPT cessation and 2-year clinical outcomes in left main/proximal LAD versus other PCI: Results from the Patterns of Non-Adherence to Dual Antiplatelet Therapy in Stented Patients (PARIS) registryJaya Chandrasekhar, Usman Baber, Samantha Sartori, et al.
Circulation. Heart Failure|January 22, 2026
Association Between the 2022 AHA/ACC/HFSA Heart Failure Staging and Cardiovascular and Kidney Outcomes in Patients With Diabetes and Kidney Disease: A Post Hoc Analysis of the SCORED Randomized Controlled TrialAyodele Odutayo, Deepak L Bhatt, Vikas S Sridhar, et al.
JACC. Cardiovascular Interventions|October 24, 2015
Stent Thrombosis in Drug-Eluting or Bare-Metal Stents in Patients Receiving Dual Antiplatelet TherapyDean J Kereiakes, Robert W Yeh, Joseph M Massaro, et al.
European Journal of Heart Failure|December 18, 2024
Association between body mass index and clinical outcomes in patients with acute myocardial infarction and reduced systolic function: Analysis of PARADISE-MI trial dataOffer Amir, Gabby Elbaz-Greener, Shemy Carasso, et al.
American Heart Journal|February 22, 2025
Oral factor xia inhibitor milvexian after a recent acute coronary syndrome: Rationale and design of the phase 3 (Librexia ACS)C Michael Gibson, M Cecilia Bahit, Roxana Mehran, et al.
American Heart Journal|October 23, 2023
Effects of complete revascularization according to age in patients with ST-segment elevation myocardial infarction and multivessel disease (COMPLETE-AGE)Kevin R Bainey, David A Wood, Matthias Bossard, et al.
Journal of the American College of Cardiology|February 25, 2014
Ticagrelor effects on myocardial infarction and the impact of event adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) trialKenneth W Mahaffey, Claes Held, Daniel M Wojdyla, et al.
Journal of Cardiac Failure|April 18, 2025
NT-proBNP in the Early Convalescent Phase after High-Risk Myocardial Infarction Is Associated with Adverse Cardiovascular Outcomes: the PARADISE-MI TrialKarola S Jering, Brian L Claggett, Eugene Braunwald, et al.
Circulation|April 1, 2020
Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS TrialDeepak L Bhatt, John W Eikelboom, Stuart J Connolly, et al.
Pageof 97

Showing results (781-790 of 962) with videos related to

Sort By:
Pageof 97
JAMA|October 28, 2010
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysisJessica L Mega, Tabassome Simon, Jean-Philippe Collet, et al.
International Journal of Cardiology|May 31, 2017
Patterns and associations between DAPT cessation and 2-year clinical outcomes in left main/proximal LAD versus other PCI: Results from the Patterns of Non-Adherence to Dual Antiplatelet Therapy in Stented Patients (PARIS) registryJaya Chandrasekhar, Usman Baber, Samantha Sartori, et al.
Circulation. Heart Failure|January 22, 2026
Association Between the 2022 AHA/ACC/HFSA Heart Failure Staging and Cardiovascular and Kidney Outcomes in Patients With Diabetes and Kidney Disease: A Post Hoc Analysis of the SCORED Randomized Controlled TrialAyodele Odutayo, Deepak L Bhatt, Vikas S Sridhar, et al.
JACC. Cardiovascular Interventions|October 24, 2015
Stent Thrombosis in Drug-Eluting or Bare-Metal Stents in Patients Receiving Dual Antiplatelet TherapyDean J Kereiakes, Robert W Yeh, Joseph M Massaro, et al.
European Journal of Heart Failure|December 18, 2024
Association between body mass index and clinical outcomes in patients with acute myocardial infarction and reduced systolic function: Analysis of PARADISE-MI trial dataOffer Amir, Gabby Elbaz-Greener, Shemy Carasso, et al.
American Heart Journal|February 22, 2025
Oral factor xia inhibitor milvexian after a recent acute coronary syndrome: Rationale and design of the phase 3 (Librexia ACS)C Michael Gibson, M Cecilia Bahit, Roxana Mehran, et al.
American Heart Journal|October 23, 2023
Effects of complete revascularization according to age in patients with ST-segment elevation myocardial infarction and multivessel disease (COMPLETE-AGE)Kevin R Bainey, David A Wood, Matthias Bossard, et al.
Journal of the American College of Cardiology|February 25, 2014
Ticagrelor effects on myocardial infarction and the impact of event adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) trialKenneth W Mahaffey, Claes Held, Daniel M Wojdyla, et al.
Journal of Cardiac Failure|April 18, 2025
NT-proBNP in the Early Convalescent Phase after High-Risk Myocardial Infarction Is Associated with Adverse Cardiovascular Outcomes: the PARADISE-MI TrialKarola S Jering, Brian L Claggett, Eugene Braunwald, et al.
Circulation|April 1, 2020
Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS TrialDeepak L Bhatt, John W Eikelboom, Stuart J Connolly, et al.
Pageof 97